Did ePlus’ (PLUS) Expanded Share Authorization Quietly Redefine Its Capital Flexibility Playbook?

  • At its 2026 Annual Meeting of Shareholders held on September 10, 2026, ePlus Inc. secured board approval for a proposal to amend its Certificate of Incorporation to lift authorized common shares from 50,000,000 to 75,000,000, keeping preferred shares unchanged at 2,000,000 and raising total authorized capital stock to 77,000,000, subject to shareholder approval.
  • This planned increase in authorized common stock gives ePlus added flexibility to fund future business and financial initiatives, such as potential acquisitions, equity financing, or employee equity plans, without needing repeated shareholder votes.
  • Next, we will examine how ePlus’s planned increase in authorized common shares may influence its investment narrative and growth options.

Find 49 companies with promising cash flow potential yet trading below their fair value.

Advertisement

ePlus Investment Narrative Recap

To own ePlus, you need to be comfortable with a project-driven IT solutions business that has shown earnings growth but still faces margin pressure and customer concentration risk. The proposed increase in authorized shares mainly expands financial flexibility and does not materially change the near term reliance on large enterprise deals or the risk that recent revenue strength may not be repeatable.

Among recent announcements, the introduction and subsequent increase of the quarterly dividend, now at US$0.27 per share as of May 2026, sits alongside active share repurchases and frames this share authorization proposal in a broader capital allocation context. Together, these moves shape how investors might weigh the potential for future acquisitions or equity-funded initiatives against existing concerns about lumpy demand and operating expense growth.

Yet behind the flexibility of more authorized shares, investors should be aware of how concentrated demand in key verticals could...

Read the full narrative on ePlus (it's free!)

ePlus’ narrative projects $2.8 billion revenue and $136.4 million earnings by 2029.

Uncover how ePlus' forecasts yield a $111.00 fair value, a 25% upside to its current price.

Exploring Other Perspectives

PLUS 1-Year Stock Price Chart
PLUS 1-Year Stock Price Chart

Two fair value estimates from the Simply Wall St Community span roughly US$76.81 to US$111, underscoring how far apart individual views can be. Set that against concerns about non repeatable, project driven revenue and consider how different growth assumptions can reshape expectations for ePlus over time.

Explore 2 other fair value estimates on ePlus - why the stock might be worth as much as 25% more than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

Ready For A Different Approach?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About NasdaqGS:PLUS

ePlus

Provides information technology (IT) solutions that enable organizations to optimize IT environment and supply chain processes in the United States and internationally.

Excellent balance sheet with proven track record.

Advertisement

Weekly Picks

LO
Lou_Basenese
OPTH logo
Lou_Basenese on Optimi Health ·

The Only Psychedelic Company Already Selling MDMA and Psilocybin to Real Patients, Yet Priced Like It Doesn’t Exist

Fair Value:US$1157.5% undervalued
38 users have followed this narrative
2 users have commented on this narrative
6 users have liked this narrative
WE
WealthAP
NOVO B logo
WealthAP on Novo Nordisk ·

Novo Nordisk (NVO): Is the "Easy Growth" Story Over?

Fair Value:DKK 407.7721.4% undervalued
59 users have followed this narrative
0 users have commented on this narrative
7 users have liked this narrative
VA
ValueInvestingSubstack
ZTS logo
ValueInvestingSubstack on Zoetis ·

Zoetis down -50% over the past year

Fair Value:US$92.9218.9% undervalued
21 users have followed this narrative
0 users have commented on this narrative
8 users have liked this narrative
CE
CentryResearch
LEU logo
CentryResearch on Centrus Energy ·

Centrus Energy: The Next Nuclear Bottleneck Isn't Reactors. It's Fuel.

Fair Value:US$19013.7% undervalued
19 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative

Updated Narratives

AE
ASML logo
Aequitas on ASML Holding ·

ASML Will Reign as the Kingpin of the Semiconductor Supply Chain

Fair Value:€1.87k16.5% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
AE
FTNT logo
Aequitas on Fortinet ·

Fortinet, compounding Cyber Security Player.

Fair Value:US$116.8430.4% overvalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
AE
CSU logo
Aequitas on Constellation Software ·

Constellation Software: A Proven Serial Acquirer at a Discount

Fair Value:CA$3.72k28.3% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

BE
PYPL logo
benjamin_lvieq on PayPal Holdings ·

PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

Fair Value:US$6513.6% undervalued
70 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative
CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.919.1% undervalued
72 users have followed this narrative
0 users have commented on this narrative
5 users have liked this narrative
TR
tripledub
GOOGL logo
tripledub on Alphabet ·

Warren Buffett Just Bet $10 Billion on Google. The Catch? You May Already Be Too Late.

Fair Value:US$23039.0% overvalued
94 users have followed this narrative
1 users have commented on this narrative
18 users have liked this narrative

Trending Discussion

DE
TDOC logo
derek_3wsdg on Teladoc Health ·

You’ve overlooked the activist investor factor. Travis Cocke’s Voss has announced 5% ownership through a 13G filing. They’ve added to that 5% since, and in doing so, have created a structural trap door for 27.42 Million Shares actively sold short. Chuck will announce lots of positives on July 29 but it’s what Voss announces shortly after that will rock the overextended Teledoc shorts. The Walmart partnership is the tip of the iceberg. The market is missing the sheer regulatory and enterprise friction of modern corporate healthcare. Teladoc isn't a "consumer app"; it is the primary digital infrastructure integrated directly into the legacy backends of Tier-1 insurance companies and fortune 500 employers, covering 105 million+ lives. Teladoc is acting as the digital top-of-funnel engine for the world's largest retailer. If Voss pushes the narrative that Teladoc is effectively the outsourced digital brain of Walmart's entire healthcare footprint, the fair value shifts from a basic health multiple to an enterprise distribution premium. Additionally , we are in a structural gold rush for high-quality, legally compliant, longitudinal medical data to train vertical healthcare AI models. Large technology hyperscalers and pharmaceutical giants cannot simply scrape the internet for this; they need structured clinical inputs. Teladoc sits on one of the largest de-identified virtual medical datasets on earth. From the activist playbook , we’ll see Voss demand the immediate creation of a Data & Diagnostics Licensing Division, transforming a legacy liability into an incredibly high-margin, pure-software data asset that requires zero human clinician hours to scale. Chuck is doing great work and deserves credi5 for the Teledoc turnaround but it will be Travis Cocke who will be responsible for a share price way beyond your $15 valuation.

0
|
0